Twenty-five years after "Wingspread"- Environmental endocrine disruptors (EDCs) and human health.

The aim of this paper is to provide the reader with a view of the Endocrine Disruptor Chemical (EDC) research field and its relevance to human health. My perspective is from working on the effects of EDCs that act via the androgen (A) or estrogen (E) signaling pathways in a regulatory agency for the last four decades with the objective of producing data that risk assessors could use to reduce the uncertainty in risk assessment. In vitro and in vivo data from our studies has contributed to regulatory agencies decision-making since the 1990s (https://www3.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-113201_7-Apr-98_238.pdf). From the start, we were evaluating the utility of in vitro and short-term in vivo effects to predict the adverse effects in developing animals [1; 2]. This approach has expanded greatly to include what is now known as Adverse Outcome Pathways (AOP) and networks (AOPn) [3; 4]. The AOP framework for the effects of chemicals that disrupt androgen signaling during sexual differentiation of the fetal male rat provides biological context for extrapolating mechanistic information from in vitro and in vivo assays in rodents to other species including humans. Such an approach has biological validity because the E and A pathways are highly conserved in vertebrates, including humans and laboratory animals.